AML arising from MDS
Showing 1 - 25 of 2,953
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +5 more
- Gemtuzumab Ozogamicin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)
Not yet recruiting
- AML/MDS
- +2 more
- Danvatirsen
- Danvatirsen + Venetoclax
- (no location specified)
Aug 14, 2023
AML, MDS Trial in Tianjin (XZB-0004)
Not yet recruiting
- AML
- MDS
-
Tianjin, Tianjin, ChinaHematology Hospital, Chinese Academy of Medical Sciences
Feb 13, 2023
Cancer, MDS-EB, MDS Trial in Athens, Southampton, Sheffield (INKmune)
Recruiting
- Cancer
- +4 more
- INKmune
-
Athens, Attiki, Greece
- +2 more
Jul 3, 2023
AML, MDS Trial in Tuebingen (Decitabine, Venetoclax)
Recruiting
- AML
- MDS
-
Tuebingen, Baden-Wuerttemberg, GermanyUniversity Hospital
Nov 30, 2023
Immunophenotyping of Blast Cells and Immune Effector Cells in
Completed
- Leukemia
- Blood and Marrow sample
-
Marseille, FranceAssistance Publique - Hopitaux de Marseille
Jan 23, 2023
Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Neoplasm
- Magrolimab
- +2 more
- (no location specified)
Apr 24, 2023
MDS, Myeloid Leukemia, Allogeneic Stem Cell Transplantation Trial in Pittsburgh (IFN-? (interferon gamma-1b) injection)
Recruiting
- Myelodysplastic Syndromes
- +2 more
- IFN-γ (interferon gamma-1b) injection
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Jan 5, 2023
Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Minneapolis (N-803)
Completed
- Acute Myelogenous Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Jan 4, 2023
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)
Active, not recruiting
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Gemtuzumab Ozogamicin
-
Valhalla, New YorkNew York Medical College
Sep 26, 2022
Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML) Trial in Seoul
Active, not recruiting
- Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
-
Seoul, Korea, Republic ofAsan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT) Trial in Pittsburgh
Active, not recruiting
- Acute Myeloid Leukemia (AML)
- +2 more
- Reduced-Intensity Conditioning Regimen
- Myeloablative Conditioning Regimen
-
Pittsburgh, PennsylvaniaUPMC Children's Hospital of Pittsburgh
Jan 4, 2023
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia
Recruiting
- Acute Lymphoblastic Leukemia
- +11 more
- Cyclosporine
- +8 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 29, 2022
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Boston (biological, procedure, drug)
Terminated
- Myelodysplastic Syndrome
- +2 more
- GVAX
- +6 more
-
Boston, Massachusetts
- +3 more
Jun 30, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Baltimore (Azacitidine, Sargramostim)
Completed
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Azacitidine
- Sargramostim
-
Baltimore, MarylandThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sep 23, 2022
Acute Myeloid Leukemia, MDS Trial (Cladribine, Cytarabine, Decitabine)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Cladribine
- +4 more
- (no location specified)
Mar 1, 2023
AML Including AML de Novo and AML Secondary to MDS, DLBCL Trial (Birabresib Dose 20 mg)
Terminated
- AML Including AML de Novo and AML Secondary to MDS
- DLBCL
- Birabresib Dose 20 mg
- (no location specified)
Aug 23, 2022
Acute Myeloid Leukemia, MDS Trial (Galinpepimut-S)
Available
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Galinpepimut-S
- (no location specified)
Oct 20, 2022
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)
Active, not recruiting
- Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome (MDS)
- HDM201
- +2 more
-
Durham, North Carolina
- +8 more
Dec 13, 2022
Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, MDS Trial in Minneapolis, Saint Louis, Rochester (Decitabine,
Completed
- Acute Myeloid Leukemia
- +2 more
- Decitabine
- +2 more
-
Minneapolis, Minnesota
- +2 more
Nov 2, 2022
MDS, Secondary Acute Myeloid Leukemia Trial in Tampa (CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes,
Recruiting
- Myelodysplastic Syndromes
- Secondary Acute Myeloid Leukemia
- CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
- Standard of Care Chemotherapy
-
Tampa, FloridaMoffitt Cancer Center
Sep 27, 2022
Acute Myeloid Leukemia, Myelodysplasia Trial in United States (MGTA-117)
Recruiting
- Acute Myeloid Leukemia
- Myelodysplasia
- MGTA-117
-
Duarte, California
- +7 more
Nov 23, 2022